Navigation Links
Amsterdam Molecular Therapeutics Initiates Program for Late Stage Liver Cirrhosis and Reports Strong Progress in AMT-011 With Trial Fully Recruited and European and US Submission On Track for First Half of 2008
Date:11/27/2007

ve been injected with AMT-011, completing the first 2 dose cohorts. The remaining 8 patients will be injected before the end of February, allowing the Company to file for registration with the EMEA, FDA and Health Canada before the end of the first half of 2008.

Conference call and webcast presentation

AMT will conduct a conference call open to the public today at 10.30 CET, which will also be webcast. Netherlands dial in: +31(0)800-949-4517 (toll free); US dial in: +1-866-291-4166 (toll free); UK dial in: +44-207-107-0611. The webcast can be accessed on the investors portion of AMT's website at http://www.amtpharma.com. Please go to the website 15 minutes prior to the call to register, download and install the necessary audio software. Playback of the call will be availably for 24 hours after the call. Dial in: +41-91-612-4330; +44-20-7108-6233; or +1-866-416-2558. ID 428#. The archived webcast also will be available for replay shortly after the close of the call.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with six products at different stages of development.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates,
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine news :

1. Chiltern to Participate at the Partnerships in Clinical Trials Conference in Amsterdam
2. A new molecular zip code, and a new drug target for Huntingtons disease
3. New knock-out gene model provides molecular clues to breast cancer
4. Molecular probe paints cancer cells in living animals, Stanford researchers find
5. Story ideas from molecular & cellular proteomics
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
8. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
9. Molecular profiling can accurately predict survival in colon cancer patients
10. Xceed Molecular Names Fran Tuttle to Its Board of Trustees
11. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Vegas Hotel Escapes, the premier Las ... new vacation packages for the upcoming memorial day ... for this patriotic holiday will be pleased to ... new special pricing available on VegasHotelEscapes.com's website. , ... the lowest prices possible on vacation packages to ...
(Date:5/23/2013)... May 23, 2013 Funeral Financials is ... Day to the EOD Memorial Foundation Funeral ... the greatest victims from the war. , According ... in 1941 before the U.S. was even at war. ... are identified with the Explosive Ordnance Disposal Badge. EOD ...
(Date:5/23/2013)... 23 (HealthDay News) -- A modified version of ... brain tumors, preliminary research suggests. Scientists at ... known as PVSRIPO, uses an engineered form of ... but attacks cancer cells. The therapy shows promise ... and aggressive brain tumor, they said. "These ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 “Talk. They ... campaign that empowers parents to talk to children as ... underage drinking, was launched today by the Substance Abuse ... kickoff occurred in conjunction with SAMHSA’s 2013 National Prevention ... and action around, substance abuse and mental health issues. ...
(Date:5/23/2013)... next generation genomic analysis to determine that some of ... origins, which may help in predicting cancer progression. The ... Research . , "This is the first study to ... Gleason patterns in the same tumor allowing us to ... M.D., Mayo Clinic pathologist and one of the authors ...
Breaking Medicine News(10 mins):Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 2Health News:Funeral Financials Asks Americans to Donate their Memorial Day Beer Money to Help EOD Scholarship 3Health News:Modified Polio Virus May Help Fight Brain Tumors, Study Suggests 2Health News:New Campaign to Help Parents Talk to Younger Children About the Dangers of Underage Drinking 2Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2
... In ... of Technical Personnel in Ophthalmology (ATPO) proudly launched a new tool for ophthalmic professionals: ... , ... Paul, MN (Vocus) November 10, 2009 -- Compact, informative, and convenient are just a ...
... Darden Food Supplier Eliminates Workers Health and Retirement Benefits ... members from Teamster Local Union 890 presented Darden Restaurant Group, ... a letter today directed to Darden CEO Clarence Otis. In ... workers from Hollister, CA are seeking justice after a key ...
... Pa., Nov. 10 InfoLogix, Inc. (Nasdaq: IFLG ... for the healthcare and commercial industries, today announced that ... to NASDAQ,s stockholder approval requirements, in accordance with NASDAQ ... this exception to complete a proposed plan of restructuring, ...
... Nov. 10 Roxane Laboratories, Inc. announced today the ... Perindopril Erbumine Tablets, 2mg, 4mg and 8mg by the ... available in bottles of 100 for immediate shipment to ... Tablets are AB rated to ACEON® (perindopril erbumine) tablets. ...
... , ... Rounds -- "What I,ve Learned About the Throwing Arm in the Last 30 Years" ... Gulf Breeze, Fla. (Vocus) November ... Andrews Institute will hold its inaugural Grand Rounds presentation on November, 19, 2009 at ...
... of vascular risk can be simplified, researchers say ... gauge blood cholesterol to determine vascular disease risk can ... measures levels of either total or high-density lipoprotein (HDL, ... that help transport cholesterol), without the need to have ...
Cached Medicine News:Health News:JCAHPO/ATPO Pocket Guide Launches for Eye Care Professionals 2Health News:JCAHPO/ATPO Pocket Guide Launches for Eye Care Professionals 3Health News:Teamsters Look to Darden Restaurant Group for Justice 2Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 2Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 3Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 4Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 5Health News:Roxane Laboratories, Inc. Announces the Launch of Perindopril Erbumine Tablets 2Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 2Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 3Health News:Cholesterol Measurements May Be Made Easier 2
(Date:5/23/2013)... , May 23, 2013  Intercept Pharmaceuticals, Inc. ... biopharmaceutical company focused on the development and commercialization of ... such as primary biliary cirrhosis, today announced that ... Executive Officer, will present at the Deutsche Bank Securities ... on Wednesday, May 29, 2013 at 4:10 ...
(Date:5/23/2013)...  Omeros Corporation (NASDAQ: OMER ) ... (IND) to evaluate OMS824 in Huntington,s disease has ... Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), ... linked to a wide range of diseases that ... has shown promising results in animal models directly ...
(Date:5/23/2013)... 23, 2013  MedVantx, Inc., the company that has ... announced today the Company has completed a major expansion ... pharmaceutical products and the upgrade of its systems to ... in its specialty home delivery pharmacy in ... pharmaceutical manufacturers, physicians, health systems and payors novel distribution ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 2MedVantx Achieves Significant Milestone of Managing $1.5B in Prescription Medications and Completes Facilities Expansion While Upgrading To Offer Current Good Manufacturer Practices (cGMP)-level Quality Systems in their Home Delivery Pharmacy 3
... ... Study, Pharmacokinetic Study Demonstrates Lack of Systemic Exposure of XIAFLEX, ... Conference call scheduled for today, June 3, at 8:45 a.m. Eastern Time, ... positive top-line,efficacy and safety results from the CORD I and CORD II phase ...
... 2 Alliance,Pharmaceutical Corp. (OTC Bulletin Board: ALLP) announced ... the two proposals put to the,shareholders at its Annual ... first proposal related to the re-election of each of ... additional term of one year or,until their successors are ...
Cached Medicine Technology:Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 2Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 3Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 4Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 5Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 6Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 7Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 8Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 9Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 10Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture 11Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: